No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
96 |
4. Check minimum number of eventsNone |
96 |
5. Include endpointsNone |
96 |
6. Filter based on genotype QC (FinnGen only) |
96 |
Control definitions (FinnGen only)
- Control exclude
- N14_GLOMERULAR
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- N00-N08
- Name in latin
- Nephropathia hereditaria non alibi classificata
Similar endpoints
↥List of similar endpoints to
Hereditary nephropathy, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Glomerulonephritis
- Glomerular diseases
- Genitourinary diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 696 | 397 | 292 |
| Only index persons | 604 | 359 | 245 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 56.77 | 56.15 | 57.22 |
| Only index persons | 54.59 | 53.86 | 55.65 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 96 | 51 | 45 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 57.20 | 54.87 | 59.84 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 87
- Matched controls
- 867
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N07.4
ICD-10 Finland
Hereditary nephropathy, not elsewhere classified, diffuse endocapillary proliferative glomerulonephritis
+∞
40.9
36
*
N07.3
ICD-10 Finland
Hereditary nephropathy, not elsewhere classified, diffuse mesangial proliferative glomerulonephritis
+∞
29.9
27
*
M07.3
ICD-10 Finland
Other psoriatic arthropathies
51.0
17.2
20
5
L40.5
ICD-10 Finland
Arthropathic psoriasis
51.0
17.2
20
5
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
32.0
17.0
22
9
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
8.1
11.8
28
48
R07.4
ICD-10 Finland
Chest pain, unspecified
5.1
11.3
46
156
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
14.7
9.8
16
13
N07.9
ICD-10 Finland
Hereditary nephropathy, not elsewhere classified, unspecified
+∞
9.5
9
*
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
8.5
8
*
J01FF01
ATC
clindamycin; systemic
4.2
8.3
39
142
L40.0
ICD-10 Finland
Psoriasis vulgaris
9.1
7.8
16
21
E000001
ATC
NA
4.3
7.6
32
104
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
7.9
7.2
16
24
L04AA01
ATC
[U] ciclosporin; systemic
43.5
6.9
8
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
24.8
6.8
9
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
24.8
6.8
9
*
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
5.6
6.6
19
41
A02BC01
ATC
omeprazole; systemic
3.5
6.6
38
159
D05AX52
ATC
calcipotriol, combinations; topical
8.1
6.5
14
20
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
6.3
6
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.4
6.2
14
22
R50.9
ICD-10 Finland
Fever, unspecified
4.4
6.2
23
66
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
23
68
4.13
7.24
39.8
5.7
1.3
1.3
mmol/l
0.09
23
63
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
17
7.18
6.94
6.6
2.0
0.3
0.3
u/ml
—
6
7
68
412
3.23
6.54
23.6
6.1
1.2
1.2
mmol/l
0.52
60
347
58
330
2.91
6.10
6.4
4.0
30.4
41.3
ng/l
0.39
39
240
18
57
3.66
5.07
2.9
1.5
—
—
—
0
0
61
384
2.61
4.86
23.9
5.4
1.2
1.2
mmol/l
0.01
56
338
31
144
2.70
4.57
7.0
2.7
0.6
0.8
e6/l
0.58
25
86
16
51
3.56
4.44
4.6
3.5
1.5
1.5
mmol/l
—
8
37
50
302
2.37
4.15
7.7
3.3
—
—
—
0
0
15
48
3.52
4.13
65.1
7.1
23.8
24.6
mmol/l
0.39
15
48
55
352
2.32
3.93
8.8
4.0
34.0
35.1
g/l
0.56
50
330
41
242
2.21
3.45
7.9
3.0
0.4
0.5
e6/l
0.06
36
178
57
386
2.17
3.36
11.2
5.6
0.0
0.0
estimate
0.00
12
78
57
386
2.17
3.36
7.7
4.1
0.0
0.0
estimate
0.00
11
80
10
28
3.87
3.29
1.1
1.3
—
—
—
0
0
27
137
2.35
3.21
7.8
2.9
2.9
2.6
e6/l
0.05
21
80
9
20
4.85
3.20
2.7
1.3
24.1
24.6
mmol/l
—
9
14
14
51
3.04
3.14
44.2
8.1
93.9
94.4
%
0.25
14
51
26
133
2.31
3.02
2.3
1.8
—
—
—
0
0
45
287
2.07
3.02
4.3
3.3
2.3
2.4
mmol/l
0.57
38
245
56
388
2.06
2.99
7.8
4.1
0.0
0.0
estimate
0.00
12
75
23
112
2.39
2.98
4.3
2.1
11.6
14.5
umol/l
0.94
23
101
13
47
3.04
2.95
5.2
3.6
0.0
0.1
e6/l
1.15
13
47
32
181
2.15
2.92
4.6
1.6
1.0
1.1
mg/l
0.17
25
142
15
60
2.78
2.86
7.1
3.9
49.4
53.9
ml/min/173m2
—
7
28
5
6
8.70
2.78
3.2
3.7
—
—
—
0
0
49
333
1.96
2.67
3.6
2.3
76.0
76.1
nmol/l
0.01
42
288
64
477
2.03
2.66
20.3
4.5
7.1
6.7
mmol/l
0.71
64
441
27
149
2.13
2.59
5.3
3.3
522.9
158.9
ng/l
0.69
18
123
45
301
1.93
2.53
7.1
4.3
—
—
—
0
0
19
92
2.33
2.48
1.8
1.6
—
—
—
0
0
11
41
2.90
2.37
6.5
2.5
25.1
24.6
mmol/l
0.23
11
41
11
41
2.90
2.37
25.5
2.5
0.8
0.8
%
0.16
11
41
11
42
2.83
2.27
25.5
2.5
1.9
1.1
%
0.40
11
42
5
9
5.79
2.24
1.2
1.3
—
—
—
0
0
12
49
2.66
2.20
25.8
2.6
122.2
131.9
g/l
1.11
12
49
7
19
3.89
2.19
15.0
1.6
207.1
202.1
%
—
7
19
11
43
2.76
2.18
7.7
2.8
47.6
43.9
%
0.22
11
43
16
76
2.33
2.17
3.4
2.6
0.2
0.2
g/l
0.20
16
68
5
10
5.20
2.09
1.0
1.0
—
—
—
0
0
5
10
5.20
2.09
1.2
1.3
—
—
—
0
0
9
32
3.00
2.06
1.8
1.6
—
—
—
0
0
8
27
3.14
1.98
1.0
1.4
—
—
—
0
0
18
95
2.10
1.91
1.9
1.7
—
—
—
0
0
26
158
1.89
1.88
1.8
1.7
795.1
1210.9
nmol/l
1.90
17
125
6
17
3.69
1.87
2.5
1.3
—
—
—
0
0
32
210
1.79
1.81
6.5
4.3
0.0
0.0
estimate
—
10
76
11
49
2.41
1.71
1.4
1.4
—
—
—
0
0
24
147
1.84
1.68
1.3
1.3
1.3
2.5
u/ml
—
9
55
11
50
2.36
1.64
1.4
1.5
—
—
—
0
0
5
14
3.71
1.63
1.8
1.3
—
—
—
0
0
6
20
3.13
1.61
1.0
1.6
—
—
—
0
0
5
15
3.46
1.54
1.2
1.5
—
—
—
0
0
6
21
2.98
1.53
1.7
1.5
—
—
—
0
0
6
21
2.98
1.53
1.7
1.5
—
—
—
0
0
46
351
1.60
1.43
6.2
4.1
—
—
—
0
0
20
123
1.79
1.38
1.5
1.5
—
—
—
0
0
43
327
1.57
1.33
2.3
1.9
89.4
92.9
pmol/l
0.20
21
154
86
777
2.03
1.29
40.3
15.2
19.8
22.3
mg/l
0.48
79
631
62
515
1.58
1.29
6.2
3.0
89.5
48.7
u/l
1.23
53
483
25
168
1.66
1.27
1.4
1.2
0.5
1.9
u/ml
—
8
49
73
634
1.63
1.21
16.7
8.0
90.4
81.4
u/l
0.37
68
592
26
179
1.62
1.20
5.2
2.3
—
—
—
0
0
8
39
2.14
1.18
1.0
1.0
—
—
—
0
0
24
163
1.63
1.17
1.8
1.8
531.3
455.0
pmol/l
0.27
19
136
7
31
2.35
1.13
3.0
1.9
—
—
—
0
0
7
31
2.35
1.13
3.6
2.1
—
—
—
0
0
7
32
2.28
1.10
1.1
1.7
—
—
—
0
0
5
21
2.45
1.10
1.6
1.6
—
—
—
0
0
5
21
2.45
1.10
1.4
1.6
—
—
—
0
0
79
706
1.67
1.10
6.1
4.8
1.9
2.0
mu/l
0.09
71
629
57
475
1.49
1.09
2.8
3.0
—
—
—
0
0
15
93
1.73
1.01
1.9
1.3
—
—
—
0
0
6
30
2.06
0.88
6.3
2.2
—
—
—
0
0
8
48
1.73
0.81
10.0
2.8
4.6
4.4
pmol/l
—
8
38
22
160
1.49
0.80
2.1
3.2
2.4
2.5
mmol/l
0.86
17
138
27
205
1.44
0.79
1.9
1.4
18.9
23.4
nmol/l
0.86
22
169
5
24
2.14
0.75
1.8
1.3
—
—
—
0
0
7
40
1.81
0.73
1.1
1.2
—
—
—
0
0
77
718
1.37
0.53
7.4
5.8
43.3
39.8
mmol/mol
1.69
71
669
5
32
1.59
0.43
1.2
1.1
—
—
—
0
0
5
32
1.59
0.43
1.2
1.1
—
—
—
0
0
11
85
1.33
0.29
12.5
9.2
—
—
—
0
0
77
742
1.19
0.22
6.2
4.8
6.1
6.0
mmol/l
0.47
67
673
0
10
0.00
0.21
0.0
1.1
—
1.7
—
0
5
75
723
1.17
0.20
5.4
4.1
1.4
1.3
mmol/l
0.59
67
657
76
736
1.16
0.17
29.7
14.3
70.9
79.3
ml/min/173m2
1.72
67
599
18
198
0.89
0.12
4.1
4.4
21.7
21.4
%
—
8
94
83
816
1.13
0.09
42.3
17.8
92.8
77.7
umol/l
1.55
83
816
8
78
1.03
0.07
4.8
4.2
—
—
—
0
0
78
767
1.09
0.07
6.3
5.0
2.6
2.7
mmol/l
0.71
70
702
76
754
1.04
0.00
5.9
4.5
1.4
1.5
mmol/l
0.26
69
689
76
755
1.03
0.00
5.9
4.5
4.5
4.6
mmol/l
0.59
70
696
0
5
0.00
0.00
0.0
2.4
—
18.9
—
0
5
6
64
0.93
0.00
1.7
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
157.2
—
0
7
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
29.8
—
0
7
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
5
58
0.85
0.00
1.8
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint N14_NEPHROPATHYHER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_NEPHROPATHYHER | 1.877 [1.41, 2.5] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.831 |
During the follow-up period (1.1.1998 — 31.12.2019), 104 out of 364 females with N14_NEPHROPATHYHER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_NEPHROPATHYHER | 2.079 [1.56, 2.77] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 106 out of 265 males with N14_NEPHROPATHYHER died.
Mortality risk
Mortality risk for people of age
years, who have N14_NEPHROPATHYHER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.211% | 0.338% |
| 5 | 1.2% | 2.306% |
| 10 | 3.01% | 5.455% |
| 15 | 5.937% | 10.541% |
| 20 | 10.864% | 17.371% |
Relationships between endpoints
↥Index endpoint: N14_NEPHROPATHYHER – Hereditary nephropathy, not elsewhere classified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data